Cibus ( ) - 株価, ニュースと分析Nasdaq:CBUS

CBUS 株式概要

農業バイオテクノロジー企業であるシバス社は、植物形質を開発し、種苗会社にライセンス供与してロイヤリティを得ている。詳細

CBUS ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	2/6
配当金	0/6

報酬

収益は年間64.65%増加すると予測されています

リスク分析

過去3か月間の株価の変動は非常に激しい

キャッシュランウェイが1年未満である

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

過去1年間で株主の希薄化が進んだ

+1 さらなるリスク

Cibus, Inc. 競合他社

I-Mab

NasdaqGM:IMAB

US$84.7m

uniQure

NasdaqGS:QURE

US$329.0m

Sage Therapeutics

NasdaqGM:SAGE

US$312.0m

vTv Therapeutics

NasdaqCM:VTVT

US$52.4m

価格と性能

の歴代最高値、変動、値下がりまとめCibus
過去の株価
現在の株価	US$4.53
52週高値	US$23.18
52週安値	US$2.86
ベータ	1.79
11ヶ月の変化	26.18%
3ヶ月変化	-40.75%
1年変化	-67.64%
33年間の変化	-97.30%
5年間の変化	-97.60%
IPOからの変化	-99.19%

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

株主還元

	CBUS	US Biotechs	US 市場
7D	-14.1%	-10.9%	-2.2%
1Y	-67.6%	13.9%	30.1%

業界別リターン: CBUS過去 1 年間で13.9 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: CBUSは、過去 1 年間で30.1 % のリターンを上げたUS市場を下回りました。

価格変動

Is CBUS's price volatile compared to industry and market?
CBUS volatility
CBUS Average Weekly Movement	17.6%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

安定した株価: CBUSの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: CBUSの weekly volatility ( 18% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	183	Rory Riggs	www.cibus.com

農業バイオテクノロジー企業であるシバス社は、植物形質を開発し、種苗会社にライセンス供与してロイヤリティを得ている。その中には、農家がより高い収量を確保し、作物保護化学薬品や肥料の使用を減らすことを可能にする生産性形質と、企業が化石燃料を使用したり、その生産によって温室効果ガスが増加したりする成分を代替することを可能にする持続可能な成分が含まれる。シバス社はカリフォルニア州サンディエゴに本社を置いている。

Cibus, Inc. 基礎のまとめ

Cibus の収益と売上を時価総額と比較するとどうか。
CBUS 基礎統計学
時価総額	US$133.94m
収益（TTM）	-US$445.40m
売上高(TTM)	US$4.15m

28.9x

P/Sレシオ

-0.3x

PER（株価収益率

CBUS は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
CBUS 損益計算書（TTM）
収益	US$4.15m
売上原価	US$0
売上総利益	US$4.15m
その他の費用	US$449.55m
収益	-US$445.40m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-16.84
グロス・マージン	100.00%
純利益率	-10,724.78%
有利子負債／自己資本比率	0.5%

CBUS の長期的なパフォーマンスは？

過去の実績と比較を見る

CBUS 株式概要

報酬

リスク分析

Cibus, Inc. 競合他社

NasdaqGM:IMAB

US$84.7m

NasdaqGS:QURE

US$329.0m

NasdaqGM:SAGE

US$312.0m

NasdaqCM:VTVT

US$52.4m

価格と性能

最新ニュース

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated